Browse the evidence

Sleep restriction (SR) increases energy intake by 300–550 kcal/day and alters hormonal signaling (increased ghrelin, decreased leptin, reduced GLP-1) and brain reward network activity, leading to a positive energy balance and weight gain.

If you are struggling to lose weight or control your appetite, check your sleep duration. Getting less than 7 hours of sleep can significantly increase your hunger hormones and drive you to eat more calories, particularly from high-fat and high-carb foods. Prioritizing 7-8 hours of sleep is a critical, often overlooked, component of any weight loss strategy.

Once-weekly semaglutide (1.0 mg) and once-daily liraglutide (up to 1.8 mg) significantly reduce albuminuria and slow the decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes, with effects being more pronounced in patients with preexisting chronic kidney disease (eGFR <60 mL/min/1.73 m2).

If you have type 2 diabetes, especially if you have early signs of kidney stress (like reduced eGFR or albuminuria), GLP-1 receptor agonists like semaglutide (once weekly) or liraglutide (once daily) can protect your kidneys. They reduce protein in the urine (albuminuria) and slow the loss of kidney function over time. This benefit is particularly strong if your kidney function is already reduced (eGFR <60). Discuss these options with your doctor, as they may offer kidney protection beyond just blood sugar control.

In normal-weight young women, a combined diet and exercise intervention resulting in weight loss causes a significant compensatory increase in circulating ghrelin levels, whereas exercise alone without weight loss does not alter ghrelin levels.

If you are a normal-weight woman losing weight through diet and exercise, your body will naturally increase ghrelin (a hunger hormone) to compensate for the weight loss. This is a normal physiological response to the energy deficit, not necessarily a failure of willpower. However, exercise alone, without creating a weight loss, does not appear to alter these hormone levels in this population.

Obesity is strongly associated with increased oxidative stress, chronic low-grade inflammation, and an increased risk of severe outcomes in infectious diseases like COVID-19.

Maintaining a healthy weight is critical not just for metabolic health but also for reducing the risk of severe complications from respiratory infections like COVID-19. Obesity is a major predictor of severe symptoms and critical care admission.

Oral ingestion of capsinoids (non-pungent capsaicin analogs) increases whole-body energy expenditure and reduces abdominal fat in humans with metabolically active brown adipose tissue (BAT) through the activation of the TRPV1-SNS-BAT axis.

If you have detectable brown fat, taking capsinoids (6-9 mg daily) may help slightly reduce abdominal fat and increase energy expenditure. However, if you do not have active brown fat, this supplement will likely have no effect on your metabolism. It is safe for long-term use.

Green tea extract rich in catechins increases energy expenditure and reduces body fat in humans with higher brown adipose tissue (BAT) activities, likely through the activation of TRPV1/TRPA1 channels rather than COMT inhibition.

Drinking green tea extract rich in catechins daily may slightly reduce body fat (2-3%) if you have active brown fat. The benefit comes from the catechins, not just the caffeine. It is not a magic bullet and requires existing BAT activity to work.

Bedtime administration of gamma-hydroxybutyrate (GHB) at doses of 2.5–3.5 g doubles nocturnal growth hormone (GH) secretion in healthy young men by enhancing slow-wave sleep (specifically Stage IV).

For healthy young men, taking 2.5–3.5g of GHB at bedtime significantly increases growth hormone output by deepening sleep (Stage IV). This is not a muscle-building steroid but a physiological enhancer of natural sleep-related hormone pulses. It is well-tolerated in clinical settings but carries stigma due to recreational misuse; consult a physician before considering any off-label use.

The combination of naltrexone sustained-release and bupropion sustained-release (Contrave) produces a moderate, placebo-subtracted weight loss of approximately 4.5% in adults with obesity, achieved through synergistic modulation of central appetite and satiety pathways.

Contrave (naltrexone/bupropion) is a prescription medication that helps adults with obesity lose about 4.5% more body weight than placebo over several months. It works by targeting brain pathways that control hunger and the pleasure of eating. While effective, it can cause side effects like nausea, so doctors usually start with a low dose and increase it slowly. It is generally used alongside lifestyle changes like diet and exercise.

Sleep deprivation and reduced sleep duration weaken the immune response, increasing susceptibility to viral, bacterial, and parasitic infections through mechanisms such as impaired lymphocyte proliferation and altered cytokine levels.

Prioritize adequate sleep duration and quality as a primary defense against infection. Sleep deprivation directly impairs immune cell function (lymphocytes, NK cells) and cytokine signaling, making you more susceptible to colds and other infections. Treat sleep with the same importance as nutrition and training.

GLP-1 receptor agonists induce weight loss primarily through central nervous system signaling to the arcuate nucleus (specifically POMC/CART neurons) rather than peripheral mechanisms like gastric emptying.

GLP-1 medications work by signaling to your brain's appetite centers (specifically the arcuate nucleus) to reduce food intake, rather than just slowing digestion. This central mechanism is why they are effective for weight loss even when side effects like nausea subside.

Genetic variants (e.g., FTO, MC4R) influence the response to obesity treatments, including lifestyle interventions, pharmacotherapy, and bariatric surgery, with some variants predicting poorer weight loss outcomes after certain procedures.

If you are considering bariatric surgery, discuss your genetic risk (e.g., FTO status) with your surgeon. Some genetic variants may predict poorer outcomes with gastric banding, suggesting that gastric bypass might be a more effective option for you.

Type 2 diabetes acts as an independent risk factor that accelerates the progression of nonalcoholic fatty liver disease (NAFLD) to advanced fibrosis and cirrhosis, and conversely, NAFLD predicts the development of type 2 diabetes.

If you have Type 2 Diabetes or Prediabetes, your liver health is inextricably linked to your blood sugar control. Managing your glucose and insulin levels is not just about preventing complications elsewhere; it is a primary strategy to stop fatty liver from progressing to serious scarring (fibrosis). Conversely, treating liver inflammation may help stabilize your diabetes risk. Regular screening for liver fibrosis is critical for this population.

Dietary cholesterol is a distinct and critical risk factor for the progression of NAFLD to NASH, driving inflammation and oxidative stress independently of total lipid accumulation.

For those with fatty liver, paying attention to dietary cholesterol intake may be important for preventing progression to more severe liver disease (NASH). This includes limiting high-cholesterol foods, as the liver's ability to handle cholesterol is compromised in NAFLD, leading to inflammation.

In insulin-resistant subjects, a carbohydrate-rich diet redistributes body fat to central depots and decreases postprandial peripheral adiponectin gene expression, whereas a monounsaturated fat (MUFA)-rich diet prevents this central fat redistribution and maintains higher adiponectin expression.

If you are insulin resistant, eating a high-carbohydrate diet may cause your body to store fat in your belly (central depot) and reduce protective adiponectin levels, even if you don't gain overall weight. Switching to a diet rich in monounsaturated fats (like olive oil) can help prevent this central fat accumulation and maintain better insulin sensitivity compared to high-carb or high-saturated-fat diets, provided total calories remain stable.

Increased body adiposity, specifically higher BMI and adult weight gain, significantly increases the risk of breast cancer in postmenopausal women, particularly for hormone receptor-positive (HR+) tumors.

Maintain a healthy body weight and avoid adult weight gain to reduce breast cancer risk after menopause. This is especially important for preventing hormone receptor-positive breast cancers.

Attenuated (slow) heart rate recovery (HRR) after exercise is associated with a significantly increased risk of cardiovascular events and all-cause mortality in the general population.

To assess your long-term cardiovascular risk, measure your heart rate immediately after stopping moderate-to-vigorous exercise and again after 1 or 2 minutes. A smaller drop (attenuated HRR) indicates slower autonomic recovery and is linked to higher mortality risk. This is a simple, non-invasive metric you can track with any basic heart rate monitor to gauge your autonomic health and longevity risk, independent of your weight or blood pressure.

For every 10 beats per minute (bpm) decrement in heart rate recovery, the risk of cardiovascular events increases by 13% and all-cause mortality by 9%.

Your heart rate recovery speed matters incrementally. Each 10 bpm drop in your heart rate during the first 1-2 minutes after exercise is associated with a 9-13% reduction in your risk of death or heart disease. Improving this recovery speed through consistent aerobic training is a direct lever for longevity.

Genetic variation in the IL15RA gene (specifically the PstI polymorphism in exon 7) is strongly associated with greater muscle hypertrophy (lean mass gain) in response to resistance exercise training, although it is associated with reduced muscle quality gains.

Your genetics influence how much muscle you gain from resistance training, specifically through the IL-15 receptor pathway. While you cannot change your DNA, understanding that genetic variation explains some of the 'non-responder' phenomenon can help manage expectations. Focus on consistent resistance training (3x/week, 75-80% 1RM) as the primary driver of change, knowing that genetic factors will modulate the final outcome.

While IL15RA genetic variation (PstI polymorphism) is associated with greater muscle hypertrophy, it is also associated with reduced muscle quality (strength relative to muscle size) gains.

If you have genetic variants associated with high hypertrophy but low muscle quality, you may gain size without a proportional increase in strength. To counter this, prioritize strength-focused training (lower reps, higher load) alongside hypertrophy work to ensure neuromuscular adaptations keep pace with muscle growth.

Ether-linked phosphatidylethanolamines (specifically PE-P and PE-O) are associated with lower insulin resistance (SSPG) and healthier metabolic profiles, contrasting with other lipid classes like Ceramides and TAGs which increase with IR.

Not all phosphatidylethanolamines are equal. Ether-linked forms (PE-P and PE-O) are associated with lower insulin resistance, while standard PEs and Ceramides are linked to higher resistance. This highlights the importance of lipid subclass specificity in metabolic health.

Five nights of sleep restriction (4 hours time in bed) impairs glucose metabolism by increasing post-prandial glucose and insulin levels, while simultaneously increasing afternoon/evening cortisol and decreasing sex hormone binding globulin (SHBG).

If you are a healthy young man, restricting your sleep to 4 hours for five nights will significantly impair your body's ability to handle glucose after meals, even if your fasting blood sugar looks normal. This is accompanied by higher stress hormones (cortisol) and lower SHBG. To mitigate this, prioritize getting adequate sleep (7-9 hours) as it is a critical lever for metabolic health, comparable to diet and exercise.

High-intensity physical activity, particularly when performed in the evening or close to bedtime, is associated with poor sleep quality and difficulty initiating sleep.

If you exercise in the evening, avoid high-intensity workouts within 3 hours of bedtime. Opt for moderate intensity or finish your session earlier in the evening. High-intensity or long-duration (>90 min) evening exercise is linked to poorer sleep quality.

Short-term meal satiety signals (like CCK) are modulated by the strength of long-term adiposity signals (insulin and leptin); higher adiposity signals increase sensitivity to satiety cues, reducing meal size.

Your body adjusts how sensitive you are to fullness signals based on your fat stores. When fat stores are high, your body may become less sensitive to 'I'm full' signals, leading to larger meals. Recognizing this biological driver can help in managing expectations during weight loss.

Carbohydrate restriction improves Metabolic Syndrome markers (fasting glucose, insulin, triglycerides, HDL, blood pressure) independently of weight loss, with the underlying mechanism being the control of insulin metabolism.

If you have high triglycerides, high blood sugar, or low HDL, reducing your carbohydrate intake is likely to improve these markers, even if you do not lose weight. This approach targets the underlying insulin resistance associated with Metabolic Syndrome. You do not need to eat excessive amounts of fat; simply reducing carbohydrates is the key lever.